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The NFKB-2 (Lyt-10) gene codes for an NF-kB-related
transcription factor containing rel-polyG-ankyrin do-
mains. Rearrangements of the NFKB-2 locus leading to
the production of 3' truncated NFKB-2 proteins are
recurrently found in lymphoid neoplasms, particularly
cutaneous lymphomas. Such mutant NFKB-2 proteins
have lost the ability to repress transcription that is
typical of NFKB-2 subunit p52, and function as
constitutive transcriptional activators. To verify whether
the expression of abnormal NFKB-2 proteins can lead to
malignant transformations in mammalian cells, we
transfected human lymphoblastoid cell lines and murine
fibroblasts (Balb/3T3) with expression vectors carrying
the cDNAs coding for normal NFKB-2p52, Lyt-10Ca or
LB40 proteins, which are representative of the abnormal
types found in lymphoma cases. The expression of both
normal and mutant NFKB-2 proteins has a lethal eect
on lymphoblastoid cells and a cytotoxic eect was also
observed in murine fibroblasts. The fibroblast cell lines
expressing Lyt-10Ca or LB40, but not those expressing
normal NFKB-2p52, were capable of forming colonies in
soft agar. The analysis of individual clones revealed that
cloning eciency correlated with the expression levels of
the abnormal proteins. Injection of the Lyt-10Ca-
transfected Balb cells in SCID mice led to tumor
formation in all of the animals, whereas no tumors were
observed in the mice injected with control or NFKB-
2p52-transfected cells, thus indicating that abnormal
NFKB-2 protein expression is tumorigenic in vivo. Our
results show that mutant NFKB-2 proteins can lead to
the transformed phenotype, and support the hypothesis
that alterations in NFKB-2 genes may play a role in
lymphomagenesis.
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Introduction
The NF-kB proteins are a family of transcription
factors that regulate the transcription of a wide variety
of genes, including those involved in immune response
and the control of cell growth (Grilli et al., 1992;
Baeuerle and Henkel, 1994).
The NFKB-2 gene homologous to NFKB-1 (Bours et
al., 1990; Ghosh et al., 1990) encodes a 100 Kd protein
containing an N-terminal DNA binding domain (rel-
domain), a poly(G) hinge as a site of proteolytic
cleavage, and a carboxy-terminal domain containing
ankyrin repeats (Neri et al., 1991; Schmid et al., 1991;
Bours et al., 1992). NFKB-2p100 is the primary
translational product and is localized in the cyto-
plasm. The active NFKB-2p52 subunit, which retains
the rel-domain and loses the ankyrin regions, derives
from the post-translational processing of p100 and,
upon NF-kB activation, can be found in the nucleus as
part of NF-kB complexes (Mercurio et al., 1993;
Chang et al., 1994). NFKB-2p52 has no intrinsic
transcription activity, but positively regulates NF-kB
transcription when complexed with RelA or the IkB-
like protein Bcl-3; the homodimers have inhibitory
eect (Bours et al., 1993; Nolan et al., 1993; Mercurio
et al., 1993; Chang et al., 1994). NFKB-2 activity is
thus regulated at various integrated levels in both the
cytoplasm and the nucleus, and is dependent on
protein-protein interaction.
Accumulating evidence indicates that the members
of the NF-kB family may be involved in oncogenesis.
The retroviral variant of c-rel, v-rel, is a potent
oncogene in avian cells (Beug et al., 1981; Gilmore
and Temin, 1988), and chromosomal alterations
involving c-rel (Lu et al., 1991) and the IkB-related
protein, Bcl-3 (Ohno et al., 1990), have been found in
lymphoid neoplasms. The transforming activity of a
variant form of RelA called p65D has been reported,
although this finding is controversial (Narayanan et al.,
1992; Grimm and Baeuerle, 1994). Furthermore, the
expression of antisense RelA RNA reduces tumor-
igenicity (Higgins et al., 1993) and the disruption of
IkBa regulation by antisense RNA expression leads to
malignant transformation (Beauparlant et al., 1994).
With regard to NFKB-2, a number of observations
support the hypothesis that structural alterations in the
NFKB-2 locus may play a role in lymphomagenesis.
The NFKB-2 (Lyt-10) gene was originally cloned from
a chromosomal translocation t(10;14) (q24;q32) invol-
ving the IgHCa locus in a case of B-cell non Hodgkin’s
lymphoma (Neri et al., 1991); as an eect of the
chromosomal rearrangement a truncated form of the
NFKB-2 protein was encoded that lacks the ankyrin
domain and is constitutively localized in the nucleus.
Analysis of a large panel of dierent subtypes of
human lymphoid tumors indicates that NFKB-2
rearrangements are present in about 2% of cases,
including non Hodgkin’s lymphoma, chronic lympho-
cytic leukemia (B-CLL), multiple myeloma, and
particularly in cutaneous lymphomas (10%) (Frac-
chiolla et al., 1993). Molecular analysis of the
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breakpoints within the NFKB-2 gene from several cases
showed that these rearrangements can occur as a
consequence of translocations or internal deletions
leading to the removal of variable portions of the
ankyrin domain (Migliazza et al., 1994), thus suggest-
ing that truncation within the ankyrin domain may be
the general mechanism underlying the constitutive
activation of NFKB-2 in vivo. Further and more
convincing data supporting this hypothesis derive
from the functional analysis of two abnormal NFKB-
2 proteins found in B-cell lymphomas (Chang et al.,
1995), whose functional abnormalities suggest that they
can escape the physiological regulatory mechanisms of
NFKB-2 proteins, such as proteolytic processing and
retention by IkB molecules. In particular, they are
localized in the nucleus and bind DNA as primary
translational products. These proteins maintain their
ability to heterodimerize with RelA and transactivate
kB-dependent transcription, but have lost their
transcription repressing activity as homodimers and,
furthermore, may transactivate regardless of their
association with RelA or Bcl-3.
Although structural and functional analyses of
abnormal NFKB-2 proteins suggest that the NFKB-2
gene may be a protoncogene, there is still no direct
evidence of their ability to transform mammalian cells.
We addressed this point by directly analysing the
biological eects of the constitutive expression of two
abnormal NFKB-2 proteins in dierent cell lines. We
found that mouse fibroblasts expressing altered NFKB-
2 proteins are capable of growing in soft agar and
forming tumors in SCID mice, thus suggesting that
altered NFKB-2 proteins may play a role in tumor
transformation.
Results
Generation of cell lines expressing mutant NFKB-2
proteins
Our previous studies have shown that all of the
rearrangements within the NFKB-2 gene involve the
3' coding region corresponding to the ankyrin domain
(Fracchiolla et al., 1993; Migliazza et al., 1994). The
consequence of these rearrangements is the generation
of 3' truncated NFKB-2 proteins or, in a minority of
cases, fusion proteins with heterologous tails of
dierent lengths. Figure 1 schematically shows the
three abnormal NFKB-2 proteins used in our
experiments as representative models of the rearranged
proteins generated in tumor cells in vivo. The
characteristics of these proteins have already been
extensively described. Briefly, the Lyt-10Ca variant
deriving from a case of B-cell non-Hodgkin’s
lymphoma (RC685) is a fusion protein in which the
first ankyrin repeat is linked to a tail of 174 aa
generated by an o-frame Ca coding region (Neri et
al., 1991; Chang et al., 1995). The HUT-78p85 protein
derived from a T-cell lymphoma cell line (Zhang et al.,
1994) is a truncated form that maintains five ankyrin-
repeats. The LB40 protein was cloned from a case of
B-CLL (Migliazza et al., 1994) and is the longest
truncated protein we have found in the tumor cases
analysed so far, having its breakpoint within the sixth
ankyrin repeat. The transcriptional and DNA-binding
activities of the Lyt-10Ca and HUT-78p85 proteins
have been extensively analysed (Chang et al., 1995),
and our unpublished data indicate that the LB40
variant has similarly abnormal functional activities.
The involvement of the NFKB-2 locus in the
chromosomal rearrangements found in B-cell lympho-
ma prompted us to select human lymphoblastoid cell
lines (LCL) immortalized by the Epstein-Barr virus as
the specific targets for our experiments. Using vectors
in which the cDNAs coding for the NFKB-2p52 and
abnormal proteins were expressed under the control of
the cytomegalovirus promoter (CMV), we could not
select any survival clone in three dierent cell lines.
Assuming that the constitutive expression of the
abnormal proteins may be cytopathic for LCLs, we
used the genomic clone of Lyt-10Ca including the 5'
promoter region, in the presence of the enhancer
element of the IgH locus, in an attempt to obtain a
more regulated expression of the mutant protein. We
were able to obtain a few clones expressing Lyt-10Ca
mRNA, but none expressing Lyt-10Ca protein. On the
contrary, when transfected with CMV Lyt-10Ca the
Burkitt cell line Daudi did express Lyt-10Ca protein
(data not shown), thus suggesting that the possibility of
expressing abnormal NFKB-2 proteins in B-cells may
be related to the stage of dierentiation or to the
transformed phenotype.
Using CMV vectors, we transfected immortalized
Balb/3T3 mouse fibroblasts. Although we were unable
to obtain clones expressing HUT-78p85, we did obtain
clones expressing NFKB-2p52, Lyt-10Ca or LB40
proteins. Significantly fewer survival clones were
observed after selection in all of the transfected cell
lines expressing the three proteins than in the control
cells transfected with the vector alone (Table 1), which
suggests that the constitutive expression of the three
proteins has cytopathic eects on various cell lines.
Figure 2 shows the mRNA and protein expression of
the polyclonal transfected cells. Using the NFKB-2
cDNA fragment SmaI –HincII as a probe, RNAse
protection analysis (Figure 2a) indicated that the
NFKB-2p52, Lyt-10Ca and LB40 mRNAs have the
expected size and a similar level of expression.
Immunofluorescence analysis using anti-Lyt-10 antiser-
Figure 1 Schematic representation of normal and abnormal
NFKB-2 proteins, showing the rel, poly-G and ankyrin domains.
1 – 6 ankyrin repeats. The predicted number of amino acids (aa) of
each protein is shown on the right. The number of amino acid
residues of normal NFKB-2 protein is also indicated for each
protein
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um (Neri et al., 1991) confirmed the nuclear
localization of the transfected proteins and indicated
that the selected bulk populations were representative
of several clones with dierent levels of protein
expression (Figure 2b). EMSA analysis using HLA-
kB probe and nuclear extracts from transfected cells
revealed increased DNA binding activity in the cells
expressing Lyt-10Ca and LB-40 proteins (data not
shown). Western-blot analysis to detect RelA, RelB, c-
rel and NFKB-1 proteins indicated increased expres-
sion of NFKB-1 in the Lyt-10Ca and LB-40
transfected cells, whereas no relevant dierences in
RelA, RelB or c-rel levels were observed (data not
shown). Experiments are currently being undertaken in
order to investigate further the alterations within the
NF-kB system in Lyt-10Ca and LB-40 expressing cells.
Fibroblasts expressing Lyt-10Ca or LB40 proteins are
clonogenic in soft agar
Analysis of the morphological phenotype and growth
pattern of the transfected cells showed that the
morphology and saturation densities of the control,
NFKB-2p52, Lyt-10Ca and LB40 polyclonal cell
populations were similar; we could not detect any
dierences in their growth curves at serum concentra-
tions of 10% or even as low as 1 – 2% (data not
shown). We then analysed the ability of the cells to
grow in soft agar as an assay for the transformed
phenotype in vitro. Despite the fact that a low
background level was found in the control cells, the
cloning eciency of the Lyt-10Ca and LB40 cells was
significantly greater than that of the NFKB-2p52 or
control cells (Table 2). Moreover, the colonies in the
LB40 and Lyt-10Ca populations were much larger than
those observed in the control or NFKB-2p52 cells
(data not shown). In order to verify directly whether
this ability to form colonies in agar is related to the
expression of abnormal NFKB-2 proteins, we isolated
and analysed individual clones expressing Lyt-10Ca.
The data in Table 3 clearly indicate that there is a
direct correlation between mRNA expression and
cloning eciency.
Fibroblasts expressing Lyt-10Ca protein are tumorigenic
in vivo
We finally tested the ability of Lyt-10Ca cells to form
tumors in vivo when injected subcutaneously into SCID
mice. As shown in Table 2, only the mice injected with
Lyt-10Ca cells developed tumors (100% of the injected
mice), whereas no tumors were detected in the mice
injected with control or NFKB-2p52 cells during the
Table 1 Toxicity of NFKB-2 proteins in mouse fibroblasts
Transfected cells Exp 1* Exp2*
Balb-pCMV
Balb-pCMVp52
Balb-pCMVLyt-10Ca
Balb-pCMVLB40
153.3+23.8
36.7+6.6
23.5+5.7
46.3+7.5
197.5+17.4
54.0+6.0
37.8+4.6
57.5+8.5
*The resistent clones were scored 14 days after the cells were seeded
at 104/cells per culture dish in hygromycin-containing medium. The
average number was obtained from at least four examinations and is
followed by the standard error
1   2  3  4   5    6  7
1353 —
1078 —
872 —
603 —
310 —
281 —
271 —
234 —
194 —
118 —
Ý
364
Ý
272
Ý
135
Balb-pCEP4b
Balb-pCEP4b -p52
Balb-pCEP4b -LB40
Balb-pCEP4b -Lyt10-Ca
a b
Figure 2 Expression of NFKB-2 mRNAs and proteins in Balb/
3T3 cells. (a) RNAse protection analysis: 20 mg of total RNA
from fibroblasts transfected with plasmid pCEP4b as control (lane
3), pCEP4b-NFKB-2p52 (lane 4), pCEP4b-Lyt-10Ca (lane 5) and
pCEP4b-LB40 (lane 6) were hybridized to a32P-labeled antisense
riboprobe spanning sequences 1267 – 1631 of NFKB-2 cDNA.
tRNA was used as a negative control (lane 7). The probe and the
various protected fragments relating to NFKB-2 cDNA are
shown at the bottom. The band between markers 234 and 194 bp,
which is common to all of the transfected cells, derives from
cross-hybridization with mouse NFKB-2 mRNA. Lane 1: Probe;
lane 2: fX174 DNA markers. (b) Immunofluorescence analysis.
After selection in hygromycin, the various bulk transfected cells
were analysed using an antiserum recognizing the N-terminal
region of NFKB-2 protein
Table 2 Tumorigenicity of abnormal NFKB-2 proteins in vitro and in vivo
Tumorigenicity in vivo
Cell lines
Cloning
efficiencya
Tumors/
injectionsb
Latency timec
(>3 mm)
Survival timec
(>10 mm)
Balb-pCMV
Balb-pCMVp52
Balb-pCMVLyt-10Ca
Balb-pCMVLB40
0.046+0.007
0.023+0.003
1.206+0.103*
1.330+0.418*
0/4
0/4
4/4
ND
0
0
20.5+11
ND
0
0
44.9+5.8
ND
aColonies were examined 14 days after the cells were seeded at 103, 26103, 104 cells per culture dish. The data are the average of
at least three experiments and are followed by the standard error. b Five-week-old female SCID mice were subcutaneously injected
with 106 transfected cells. The data show the numbers of tumors of 3 mm or more versus the number of mice injected cNumber of
days+s.d. *P50.01 vs control cells. ND: not determined
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two months of observation. Two of the tumors were
excised and found to express high levels of Lyt-10Ca
mRNA (data not shown).
Discussion
Structural and functional alterations in the NFKB-2
proteins associated with lymphoid neoplasms have led
to the hypothesis that NFKB-2 gene alterations may be
involved in lymphomagenesis. In an attempt to
substantiate this hypothesis, the aim of our study was
to verify whether two lymphoma-derived abnormal
NFKB-2 proteins were capable of transforming
mammalian cells in vitro and being tumorigenic in
vivo. Our data show that the constitutive expression of
the two altered proteins in mouse fibroblasts allows
growth in soft agar and tumor formation in
immunodeficient mice. These data provide the first
evidence of the potentially oncogenic eect of altered
NFKB-2 proteins in vivo which implies that they do
play a role in lymphomagenesis.
Cytopathic eect of NFKB-2p52, Lyt-10Ca and LB40
proteins
Our attempt to express NFKB-2 proteins failed to
generate transfected human LCLs and led to the poor
clone recovery of mouse fibroblasts. The mechanisms
of this cytopathic eect (slowed or arrested growth, or
cell death) have not yet been elucidated, but they seem
to be related to the cell context and/or to the level of
protein expression, as has been observed in relation to
other oncogenes such as c- and v-rel (Gelinas and
Temin, 1988; Schwartz and Witte, 1988; Hannick and
Temin, 1989; Lu et al., 1991; Abbadie et al., 1993), v-
src (Tarpley and Temin, 1984), v-and c-abl (Ziegler et
al., 1981; Renshaw et al., 1992; Sawers et al., 1994) and
the gene encoding the Latent Membrane Protein of
EBV (Hammerschmidt et al., 1989). The fact that both
normal and mutant NFKB-2 proteins have a similar
cytophatic eect suggests that this may not be relevant
in terms of transformation.
Transforming activity of Lyt-10Ca and LB40 proteins,
and role of altered NFKB-2 proteins in lymphomagenesis
Our data show that fibroblasts expressing Lyt-10Ca
and LB40 proteins, but not those expressing normal
NFKB-2p52, are capable of growing in soft agar and
forming tumors in inmmunodeficient mice. The mutant
NFKB-2 proteins are functionally abnormal, having
lost their transcription repressing activity and acquired
constitutive transactivating activity (Chang et al.,
1994). Although the direct consequences of these
alterations are still unknown, it is conceivable that
the expression of mutant NFKB-2 proteins may lead to
changes in the composition of NF-kB complexes and
alterations in NF-kB functions. It is also possible that
these altered proteins may deregulate the expression of
target genes that preferentially bind NFKB-2-contain-
ing complexes. Our data demonstrate that the overall
eect of the functional alterations in mutant NFKB-2
proteins is the ability to induce transformed phenotype.
On the other hand, the capacity of the cells to express
these proteins seems to be related to the level of
expression and/or to one or more possibly genetic
events that silence the cytopathic eect (see Discussion
above). In the light of this, it can be speculated that the
expression of mutant NFKB-2 proteins play a role in
the transformation process only if it occurs as a
secondary or late event.
Among the NF-kB transcription factors, transform-
ing activity has only been demonstrated in relation to
v-rel (Beug et al., 1981; Gilmore and Temin, 1988),
although controversial data has been published
regarding the variant p65D (Narayanan et al., 1992;
Grimm and Baeuerle, 1994). Our data provide new
evidence that alterations in NF-kB factors may play a
role in oncogenesis. More specifically, the recurrent
associations betwen NFKB-2 rearrangements and
lymphoid neoplasms suggest that these alterations
may be involved in the pathogenesis of these tumors.
The finding that lymphoma-derived NFKB-2 proteins
are capable of transforming mammalian cells strongly
supports the hypothesis that the rearrangements in the
NFKB-2 locus leading to the production of 3'
truncated NFKB-2 proteins may be the common
mechanism of NFKB-2 activation as a genetic event
involved in lymphomagenesis.
Materials and methods
Expression vectors
An EcoRI –XhoI fragment of NFKB-2 cDNA coding for a
C-terminal truncated protein containing the rel domain
and lacking the ankyrin repeats (Neri et al., 1991), and the
EcoRI – EcoRI fragments containing the cDNA coding for
Lyt-10Ca, LB40 and Hut-78p85 variants generated by
chromosomal rearrangements (Neri et al., 1991; Migliazza
et al., 1994; Zhang et al., 1994), were blunted and cloned
into the PvuII restriction site of the expression vector
pCEP4b (Invitrogen, San Diego, CA).
Cell cultures and transfections
The Balb/3T3 fibroblast cell line was grown in Dulbecco
modified Eagle’s medium supplemented with 10% heat-
inactivated fetal calf serum (FCS). The lymphoblastoid cell
lines, CB33, UH-1 and UH-2, as well as the Burkitt cell
line Daudi, were maintained in Iscove’s medium supple-
mented with 10% FCS. To generate stable transfected cell
lines, the Balb/3T3 cells were plated at 36105 cells/100 mm
Petri dish 24 h before the experiments; the cells were
transfected according to a modified protocol of the CaPO4
precipitation method (Gu et al., 1993). Forty-eight hours
after transfection, 105 cells were seeded in selective medium
containing 300 mg/ml of hygromycin B (BMB) and
incubated at 378C in 5% CO2 for 2 weeks; single clones
Table 3 Correlation between cloning efficiency and mRNA
expression in Balb-pCMVLyt-10Ca cells
Cloning mRNA
efficiencya expressionb
Balb-pCMVLyt-10Ca
Clone 1
Clone 2
Clone 3
Bulk
0
0.08
0.33
1.19
7
+
++
+++
aThe data are the average of at least two experiments, performed in
duplicate at 103, 26103, 104 cells per culture dish. bRNA expression
was determined by RNAase protection analysis
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or pools of transfected cells were grown for further
analysis. The lymphoid cells were transfected using the
electroporation method (250 volts, 900 capacitance) and,
48 h after transfection, were grown in a selective medium
containing 300 mg/ml hygromycin B for 3 weeks.
RNA extraction and RNAse protection analysis
RNA was extracted using the guanidine isothiocyanate
method, and analysed by RNAse protection assay. An
antisense riboprobe of 364 bp (SmaI –HincII fragment of
NFKB-2 cDNA) was generated in the presence of a32 CTP.
56105 c.p.m. of riboprobe were hybridized with 20 mg of
total RNA for 16 h at 608C, and digested with RNAseT1
and RNAseA for 7 min at RT. The protected fragments
were resolved in a 6% denaturing polyacrylamide gel and
analysed by autoradiography.
Growth in soft agar
The trypsinized cells were resuspended in Iscove’s medium
containing 20% FCS and 0.3% agar (Difco). The cell
suspensions were plated at 103, 26103, 104 on a layer of
medium containing 20% FCS and 0.5% agar. Colony
growth was scored after 14 days.
Cytotoxicity assay
Forty-eight hours after transfection, the cells were seeded
at 104 into selective medium. The number of hygromycin-
resistant clones was scored after 14 days.
Indirect immunofluorescence staining
36105 cells were plated onto cover slips the day before the
experiments. After fixation in 3% paraformaldehyde in
PBS for 30 min, they were extensively washed in PBS and
permeabilized with 0.2% Triton X-100 in PBS. After being
blocked for 4 h in 3% bovine serum albumin in PBS at RT,
the cells were incubated with polyclonal antiserum 8892
(Neri et al., 1991) (1 : 2000 dilution) for 16 h at 48C. FITC-
conjugated goat IgG directed against rabbit IgG (1 : 50
dilution) were added for 30 min at RT. The slides were
extensively washed and mounted in 50% glycerol-PBS. The
photographs were taken using a Leitz Dialux microscope
(Leitz, Wetzlar, Germany).
In vivo tumorigenicity assay
Five-week-old female SCID mice (C.B-17TM/IcrCrl-scidBR)
were purchased from Charles River Laboratories (Calco,
Italy) and treated in accordance with the European
Community guidelines. They were fed and maintained
under specific pathogen-free conditions, and received
sterilized food pellets and tap water ad libitum. The mice
were challenged subcutaneously in the left inguinal region
with 0.3 ml of a single cell suspension containing 16106
cells of the various Balb/3T3 cell lines. The cages were
coded and the incidence and growth of tumors were
evaluated twice weekly, with the investigators being blind
as to the treatment the animals had received. The two
perpendicular diameters of the neoplastic masses were
measured with calipers for 60 days. The mice which were
tumor-free at the end of this period were classified as
survivors. The latency and survival times were respectively
considered as the period (in days) between the challenge
and growth of neoplastic masses with mean diameters 43
and 410 mm. Only the mice that eventually developed
tumors were considered. The mice bearing neoplastic
masses with a mean diameter 410 mm were killed, and
the tumor masses were excised and routinely processed for
histological evaluation.
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